SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Morepen Laboratories Ltd

BSE: 500288 NSE: MOREPENLAB ISIN: INE083A01026
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Morepen Laboratories Ltd belong to?
Morepen Laboratories Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Morepen Laboratories Ltd a good quality company?
Morepen Laboratories Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is Morepen Laboratories Ltd undervalued or overvalued?
Morepen Laboratories Ltd appears Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is Morepen Laboratories Ltd a good buy now?
Morepen Laboratories Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Morepen Laboratories Ltd?
Morepen Laboratories Ltd revenue growth is 1.1% for FY-2025 , which is below its 5 year CAGR of 14.4% , indicating slower growth.
Q.2 Gross Profit margin of Morepen Laboratories Ltd?
Morepen Laboratories Ltd Gross profit margin which is the profit after deduction of direct costs, is 10.4% for FY-2025 , which is in line with its 5 year median of 10.4% , indicating stable margins.
Q.3 Operating Profit Margin of Morepen Laboratories Ltd?
Morepen Laboratories Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 9.87% for FY-2025 , which is in line with its 5 year median of 9.87% indicating stable margins.
Q.4 Net Profit Margin of Morepen Laboratories Ltd?
Morepen Laboratories Ltd Net Profit Margin is 6.53% for FY-2025 , is below with its 5 year median of 6.97%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 10.4 10.4
Operating Profit Margin 9.87 9.87
Net Profit Margin 6.53 6.97
Q.5 Return on Asset of Morepen Laboratories Ltd?
Morepen Laboratories Ltd Return on Asset is 6.77%, which is below its 5 year historical median of 9.3%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Morepen Laboratories Ltd?
Morepen Laboratories Ltd Return on equity is 9.81% for FY-2025 , which is below its historical median of 13.29%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Morepen Laboratories Ltd?
Morepen Laboratories Ltd Return on capital employed is 13.29% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of Morepen Laboratories Ltd?
Morepen Laboratories Ltd Cash conversion cycle is 50 days, below its historical median of 50 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.04 1.29
ROE 9.81 13.29
ROCE 13.29 17.71
Cash Conversion Cycle 50 days 50 days
Q.9 Debt to Equity ratio of Morepen Laboratories Ltd?
Morepen Laboratories Ltd Debt-to-Equity ratio is 0.07 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Morepen Laboratories Ltd?
Morepen Laboratories Ltd Debt to cash flow from operations is 2.72 , which is at a moderate level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Morepen Laboratories Ltd?
Promoters hold 35.65% of the Morepen Laboratories Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Morepen Laboratories Ltd vs industry peers?
Morepen Laboratories Ltd revenue CAGR is 14.44% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 1,554.5 137.1
Gross Profit 161.7 15.1
Operating Profit 153 16
Net Profit 102 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.04 0.8
ROE 9.81 8.91
ROCE 13.29 11.59
Cash Conversion Cycle (days) 50.42 76

Valuation & price assessment

Q.1 Stock return of Morepen Laboratories Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 4.7% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 4.7% 1.4% 15.1% -20.1%
Q.3 Valuation ratios of Morepen Laboratories Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 38.96 28.45 40.28
Price to Book 1.85 3.74 2.77
Price to Sales 1.41 1.44 2.65
EV to EBITDA 17.56 14.77 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×